Anzeige
Mehr »
Login
Samstag, 19.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Trumps Dekret beschleunigt Antimon-Boom - Wird Global Tactical der nächste Highflyer für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLRC | ISIN: KYG549581067 | Ticker-Symbol: 3KY
Stuttgart
17.04.25
08:09 Uhr
2,460 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
HANG SENG
1-Jahres-Chart
HANSOH PHARMACEUTICAL GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
HANSOH PHARMACEUTICAL GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
2,4602,54017.04.
2,4602,50017.04.

Aktuelle News zur HANSOH PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoHANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 ...1
DiHANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10529 TABLETS ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION3
DiHSBC Research Warns US Tariffs May Dent A-Shr Earnings, Remains Bullish on Xiaomi, CR Beer, Tingyi, Hansoh Pharma41
07.04.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20122 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION3
07.04.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20108 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2
01.04.HSI Up 244 pts; HSTI Up 97 pts; CSPC PHARMA Up over 12%; HANSOH PHARMA, CENTRAL NEW EGY, AKESO, LAOPU GOLD, 3SBIO Hit New Highs7
HANSOH PHARMACEUTICAL Aktie jetzt für 0€ handeln
31.03.HSI Down 307 pts; HSTI Down 111 pts; LI NING Down over 7%; HANSOH PHARMA, WH GROUP, TS LINES, WL DELICIOUS Hit New Highs; Market Turnover Rises4
31.03.HSI Down 404 pts; HSTI Down 168 pts; BABA Down over 3%; CCB Up over 3%; HKEX Down over 3%; HANSOH PHARMA, TS LINES, WL DELICIOUS Hit New Highs13
28.03.HSI Closes at 23,426, Down 152 pts; HSTI Closes at 5,506, Down 82 pts; HAIER SMARTHOME Down over 7%; HANSOH PHARMA, YIXIN, CHINA EAST EDU, LONKING, CRYSTAL INTL Hit New Highs; Market Turnover Rises4
28.03.HSI Closes Midday at 23,368, Down 210 pts; HSTI Closes Midday at 5,495, Down 93 pts; HAIER SMARTHOME Down over 7%; HANSOH PHARMA, ZAI LAB, CHINA EAST EDU, 3SBIO, CRYSTAL INTL Hit New Highs18
21.03.HANSOH PHARMA (03692): FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 20244
21.03.HANSOH PHARMA (03692): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 20243
10.03.HANSOH PHARMA (03692): DATE OF BOARD MEETING1
10.03.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - DRUG REGISTRATION APPROVAL OF THE THIRD INDICATION OF AMEILE (AUMOLERTINIB MESILATE TABLETS) WAS GRANTED ...1
04.03.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE SECOND BIOLOGICS LICENSE APPLICATION OF XINYUE (INEBILIZUMAB INJECTION) WAS ACCEPTED BY THE NATIONAL ...3
27.02.Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab3
25.02.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 ...1
25.02.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-10561 CAPSULES ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION1
10.02.HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - A NEW INDICATION OF XINYUE (INEBILIZUMAB INJECTION) INCLUDED IN PRIORITY REVIEW AND APPROVAL PROCEDURE2
29.01.Leichte Zugewinne bei der Hansoh Pharmaceutical-Aktie (2,28 €)345Im Plus liegt gegenwärtig der Anteilsschein von Hansoh Pharmaceutical . Zuletzt zahlten Investoren für das Wertpapier 2,28 Euro. Jahreschart der Hansoh Pharmaceutical-Aktie, Stand 29.01.2025 Für der...
► Artikel lesen
Seite:  Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1